Lorenzo Guglielmetti

Inserm — France

Medicine · Health Sciences

31h-index6.3kcitations133works6.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Tuberculosis Research and Epidemiology(111), Mycobacterium research and diagnosis(45), Pneumocystis jirovecii pneumonia detection and treatment(35), Infectious Diseases and Tuberculosis(31), Diagnosis and treatment of tuberculosis(21)

Publications129 total

Estimating the effect of hepatitis C infection on multidrug-resistant tuberculosis treatment outcomes under hypothetical interventions on regimen composition and adherence
American Journal of Epidemiology·2026Open Access
Clinical standards for antimicrobial stewardship in TB care
IJTLD OPEN·2025· 1 citedOpen Access
Improving Tuberculosis Diagnosis Through Artificial Intelligence (CAD4TB) and Stool Xpert MTB/RIF Testing: A Prospective Study From Oromia, Ethiopia
Open Forum Infectious Diseases·2025Open Access
The time is now: making the case for compassionate use/pre-approval access to new TB drugs
IJTLD OPEN·2025Open Access
The Empty Medicine Cabinet: Urgent Action Needed to Resolve TB Drug Shortages in Europe
International Journal of Infectious Diseases·2025· 1 citedOpen Access
Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort study
The Lancet Regional Health - Europe·2025· 6 citedOpen Access
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial
The Lancet Respiratory Medicine·2025· 14 citedOpen Access
Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis
The Lancet Infectious Diseases·2025· 8 cited
Clinical best practices for caring for people with expanded resistance to newer TB drugs
IJTLD OPEN·2025· 5 citedOpen Access
Communicable Episode 20: Tuberculosis today
CMI Communications·2025Open Access
Equitable, personalised medicine for tuberculosis: treating patients, not diseases
The Lancet Respiratory Medicine·2025· 5 cited
A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists
Pathogens and Immunity·2025· 10 citedOpen Access
Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy
IJTLD OPEN·2025· 4 citedOpen Access
Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment
Emerging infectious diseases·2025· 5 citedOpen Access
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis
New England Journal of Medicine·2025· 55 citedOpen Access
Bedaquiline, Delamanid, Linezolid and Clofazimine for the Treatment of Rifampicin- and Fluoroquinolone-Resistant Tuberculosis (endTB-Q): A Phase 3, Open-Label, Multicentre, Randomised, Controlled, Stratified, Non-Inferiority Trial
SSRN Electronic Journal·2025· 1 citedOpen Access
Tuberculosis in adult migrants in Europe: a TBnet consensus statement
European Respiratory Journal·2024· 19 citedOpen Access
Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response
Clinical Microbiology and Infection·2024Open Access
Impact of the COVID-19 pandemic on the real-world diagnostic infrastructure for tuberculosis—An ESGMYC collaborative study
PLoS ONE·2024· 1 citedOpen Access
Reduced critical concentration might not have improved MGIT-based DST’s sensitivity to rifampicin
Antimicrobial Agents and Chemotherapy·2024· 3 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Christoph Lange(23), Nicolas Véziris(22), J. Robert(14), Emmanuelle Cambau(8), M. Jachym(8), Simon Tiberi(8), Dhiba Marigot-Outtandy(8), Éric Caumes(7), Keertan Dheda(7), Līga Kukša(7), Yazdan Yazdanpanah(7), Alexandra Aubry(7), Graham Bothamley(7), Francis Varaine(7), Charles L. Daley(6), Erik C. Böttger(6), David E. Griffith(6), Kenneth N. Olivier(6), Miguel Santín(6), Jason E. Stout(6)